The Diagnostic Technical Advisory Group (DTAG) for the WHO Global NTD Programme was formed to foster a unified approach for identifying and prioritizing diagnostic needs, and to inform WHO strategies and guidance on NTD diagnostics. The first meeting of the DTAG was held at the Inter Parliamentary Union in Geneva, Switzerland, in October 2019. The second took place virtually in October 2020, the third in June 2021, the fourth in October 2021 and the fifth in November 2022. Several disease-specific and cross-cutting DTAG subgroups have been formed, resulting in the development of target product profiles (TPPs) for new diagnostics, some of which have been published, and some of which are in production. WHO/NTD convened the sixth DTAG meeting on 14 and 15 February 2024, with the following objectives across the end-to-end process of diagnostic development: -consider updates from disease-specific subgroups and TPP production; -discuss progress made by the cross-cutting and resource mobilization subgroups; -discuss the Expert Review Panel for Diagnostics (ERPD) NTD pilot project and lessons learnt; -discuss engagement of manufacturers and developers; -discuss laboratory capacity strengthening and standardization of molecular methods; -deliberate on the priority/focus areas of engagement for the DTAG for the next 2 years.
The fifth meeting of the WHO Diagnostic Technical Advisory Group for Neglected Tropical Diseases (DTAG) was held in November 2022. The DTAG was established in 2019 to address gaps in NTD diagnostics through a harmonized approach for identifying and prioritizing diagnostic needs, and to inform WHO strategies and guidance on NTD diagnostics. The meeting addressed the end-to-end process of diagnostic development, including regulatory pathways, as we all as advocacy and resource mobilization, and engagement of diagnostics manufacturers and developers. The DTAG and its disease-specific and cross-cutting subgroups have supported and facilitated the development of several target product profiles for selected NTDs to address the critical diagnostic gaps.
In March 2022, the World Health Organization launched the Global Arbovirus Initiative, focusing initially on Aedes-borne arboviral diseases, to strengthen the coordination, communication, capacity-building, research, and the preparedness and response necessary to mitigate the growing risk of epidemics due to arboviral diseases. WHO established an independent and multidisciplinary group of experts, formalized under the name Technical Advisory Group on Arbovirus (TAG-Arbovirus), that meets to discuss and analyze the impact of arboviruses globally and provide technical, scientific and strategic considerations on arboviruses and the Global Arbovirus Initiative. The TAG-Arbovirus, supported by the WHO Arbovirus Secretariat, met in person from 20-22 June 2023 in Accra, Ghana, to provide technical feedback and advice on the priority activities of the Global Arbovirus Initiative moving forward. The meeting focused on the first pillar of monitoring risk and anticipation and included a technical review of the integrated arbovirus risk models and maps under development for WHO. The TAG also discussed priority gaps and opportunities for each of the most affected WHO regions, detection strategies for arboviruses across regional and member state endemic profiles and resource capacities, design and implementation of global data systems for arboviruses, the role of genomic surveillance, and the critical importance of risk communication and community engagement.
Concerted efforts by national programmes, supported by public–private partnerships, nongovernmental organizations, donors and academia under the auspices and coordination of the World Health Organization (WHO), have produced important achievements in the control of human African trypanosomiasis (HAT). As a consequence, the disease was targeted for elimination as a public health problem by 2020. The Sixty-sixth World Health Assembly endorsed this goal in resolution WHA66.12 on Neglected tropical diseases, adopted in 2013. National sleeping sickness control programmes (NSSCPs) are core to progressing in the control of the disease and in adapting to the different epidemiological situations. The involvement of different partners, as well as the support and trust of long-term donors, has been crucial for these achievements. More than 20 years of partnership among WHO, Sanofi and Bayer have enabled WHO to strengthen and sustain financial, technical and material support for the implementation of control activities in countries where HAT is endemic. The long-term support from the Government of Belgium, the Bill & Melinda Gates Foundation (BMGF) and other research institutions in the Democratic Republic of the Congo (DRC) has also been essential. WHO convened the fifth stakeholders meeting on the elimination of HAT due to infection with Trypanosoma brucei gambiense (g-HAT) and Trypanosoma brucei rhodesiense (r-HAT) in Geneva, Switzerland, on 7–9 June 2023. The meeting was held again in person after the coronavirus disease (COVID-19) pandemic and jointly for both forms of the disease. The previous meetings on g-HAT held in 2014, 2016 and 2018, as well as on r-HAT in 2015, 2017 and 2019, and jointly for g-HAT and r-HAT in 2021 (8) reinforced the partnership and commitment for HAT elimination and structured the mechanisms of collaboration within the WHO network for HAT elimination. The network includes NSSCPs, groups developing new tools, international and nongovernmental organizations involved in disease control, and donors. Fewer than 1000 cases of HAT annually have been reported over the past 5 years, which is a historic achievement. The area at risk has been substantially reduced. The elimination of HAT as a public health problem at the global level has been achieved. The new road map for neglected tropical diseases (NTDs) 2021−2030 (“the road map”) with the target to interrupt the transmission of g-HAT requires the strengthened and sustained efforts of all stakeholders, national authorities and partners, under WHO coordination. It will take disproportionally high efforts and innovative strategies to find the last cases of g-HAT and neutralize its transmission. Given the limited resources and other competing public health priorities, this is a challenge that requires our joint commitment.